EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Role of Interleukin-18 After Spinal Cord Injury: Mechanisms and Therapeutic Potential

Luke J Bolstad iD, Mia J LaRico iD, Thomas S Zanovich, Grant R Keith, Amgad S Hanna iD, Daniel J Hellenbrand iD

Cells · 2026

DOI: 10.3390/cells15111011 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2026. Verfasst von Luke J Bolstad und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53706, USA. Hauptthemen laut MEDLINE: Spinal Cord Injuries, Interleukin-18. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Spinal cord injury (SCI) triggers a secondary injury cascade characterized by neuroinflammation, reactive gliosis, and neuronal apoptosis. While many pro-inflammatory cytokines contributing to this cascade reach peak upregulation within 24 h, Interleukin-18 (IL-18) exhibits a delayed upregulation profile, typically peaking 7 days post-injury. This review examines the temporal regulation and cell-specific roles contributing to the rise in IL-18 after SCI. Following primary insult, damage-associated molecular patterns prime and activate the NLRP3 inflammasome, which in turn drives latent IL-18 secretion. Cellularly, microglia function as the primary producers of IL-18 via the TLR4/p38-MAPK pathway, while astrocytes serve as the primary responders through IL-18R/p65-NF-κβ signaling. The microglia-astrocyte cross-talk propagates reactive gliosis, drives neuropathic pain, facilitates neuronal loss, and potentially contributes to the formation of the astrocytic border. Targeted therapeutic interventions such as upstream inhibition of NLRP3 inflammasome assembly or direct IL-18 neutralization successfully mitigate neuroinflammation. By either inhibiting NLRP3 inflammasome activation or directly neutralizing IL-18, these treatments shift the microglial toward a protective state, restrict histological damage, and significantly improve functional recovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spinal Cord InjuriesInterleukin-18HumansAnimalsInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinMicrogliaAstrocytesSignal TransductionNeuroinflammatory Diseases

Stichwörter der Autor:innen

Interleukin-18 (IL-18)NLRP3 inflammasomemicroglia-astrocyte crosstalkneuroinflammationspinal cord injury (SCI)

Substanzen

Interleukin-18InflammasomesNLR Family, Pyrin Domain-Containing 3 Protein

Autor:innen und Institutionen

  • Department of Neurosurgery, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53706, USA.
  • Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI 53706, USA.

ORCID-Profile: Luke J Bolstad, Mia J LaRico, Amgad S Hanna, Daniel J Hellenbrand

Förderung

  • NINDS NIH HHS
  • National Institutes of Health

Zitieren

APA

Bolstad, L. J., LaRico, M. J., Zanovich, T. S., Keith, G. R., Hanna, A. S., & Hellenbrand, D. J. (2026). The Role of Interleukin-18 After Spinal Cord Injury: Mechanisms and Therapeutic Potential. Cells. https://doi.org/10.3390/cells15111011

Vancouver

Bolstad LJ, LaRico MJ, Zanovich TS, Keith GR, Hanna AS, Hellenbrand DJ. The Role of Interleukin-18 After Spinal Cord Injury: Mechanisms and Therapeutic Potential. Cells. 2026. doi:10.3390/cells15111011

BibTeX
@article{Bolstad2026,
  author = {Bolstad, Luke J and LaRico, Mia J and Zanovich, Thomas S and Keith, Grant R and Hanna, Amgad S and Hellenbrand, Daniel J},
  title = {The Role of Interleukin-18 After Spinal Cord Injury: Mechanisms and Therapeutic Potential},
  journal = {Cells},
  year = {2026},
  doi = {10.3390/cells15111011}
}
Kostenlos starten →